About: Sudipta Saha
- Website
- Details
- Associate Professor at Department of Microbiology and Biotechnology, Sister Nivedita University, Kolkata.
Posts by Sudipta Saha:
-
June 13, 2025 The Payload Revolution: Redefining the Future of Antibody-Drug Conjugates (ADCs)
-
June 13, 2025 Protein Switches: The Programmable Future of Bio-therapeutics
-
June 13, 2025 Immuno-Timebombs: The Hidden Drivers of Age-Related Illness
-
June 6, 2025 Tailored Hope: Personalized Gene Therapy Makes History
-
June 6, 2025 Advances in Liver Transplantation: New Frontiers in Organ Regeneration and Immunomodulation
-
June 6, 2025 Weighty Decisions: Drugs or Surgery for Diabetes?
-
June 6, 2025 Tirzepatide Outperforms Semaglutide in Diabetes Control
-
June 6, 2025 Sleeping Threats: Immune System’s Watch on Dormant Cancer
-
May 2, 2025 Jennifer A. Lewis: Revolutionizing Materials Science with the 2025 James Prize
-
May 2, 2025 Cancer Surgery Rethought: Immunotherapy Takes the Lead
Follow Blog via Email
Join 2,041 other subscribers-
Recent Posts
- FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
- Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
- In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
- Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
- AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
- In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
- Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
- 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
- Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
- Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
Archives
Categories
Meta